Literature DB >> 28197488

Animal models mimicking aminoglycoside-induced renal damage.

Sandra Rodríguez Salgueiro1, Lucía González Núñez2.   

Abstract

Entities:  

Keywords:  Aminoglycosides; Animal models; Kanamycin; Nephrotoxicity

Year:  2016        PMID: 28197488      PMCID: PMC5297498     

Source DB:  PubMed          Journal:  J Nephropharmacol        ISSN: 2345-4202


× No keyword cloud information.

Implication for health policy/practice/research/medical education:

Models of nephrotoxicity in rats and mice are essential to achieve a better understanding of the pathophysiology of aminoglycoside-induced damage and to consider strategies for the protection, repair and regeneration, which could be further extrapolated for their use in the clinic. Aminoglycoside antibiotics consisting gentamicin, kanamycin, amikacin and other can cause acute kidney injury (1). This is a common problem in intensive care medicine (2). It could be fatal (3) or can progress towards chronic kidney disease in survivors (4). Knowledge of the possible mechanisms involved in aminoglycoside-induced nephrotoxicity is largely due to the use of experimental animals (5). Animal models based on treatments with aminoglycosides have also been used to evaluate possible protective or regenerative strategies (6,7). The development of aminoglycoside-induced toxicity models is a complex task, because these compounds can provoke animal death due to renal toxicity and therefore all the adverse effects associated with chronic administration of the aminoglycoside cannot be ascertained (8). Rats are usually used in studies of aminoglycoside-induced nephrotoxicity, due to their similarity to human beings in terms of the histological structure of the kidneys (9). The deleterious effect of aminoglycosides on rat renal cortex is currently well characterized (5). Although renal histological structure of mice is similar to the rats, they have been used to a lesser extent (10,11). Nephrotoxicity models commonly use treatments with high doses of an aminoglycoside over a short period of time to induce acute renal injury (12). The acute models have allowed knowing the changes that aminoglycosides induce in the kidney. Epithelial cells of the proximal tubules are the major site of accumulation of these compounds (13). Although non metabolized aminoglycosides are excreted unchanged through the kidneys, a fraction of filtered aminoglycoside is reabsorbed by proximal tubular cells and causes its toxic effect (5). Nephrotoxicity due to aminoglycosides has been largely recognized as a tubule-interstitial damage, without significant changes in glomeruli. It should be attributed to an early evaluation of the kidneys, as these studies are performed mainly through acute models, in which glomerular effects are not still evident (14). More recently, it has been shown that aminoglycosides can also induce glomerular lesions, such as congestion, glomerular hypertrophy or atrophy (6), accumulation of amorphous substance in mesangial matrix (15), decreased glomerular filtration rate and other intra-glomerular alterations (5,16). Since some patients surviving after acute kidney injury can progress towards chronic kidney disease (4), chronic models of aminoglycoside induced toxicity have also been generated. In these models, the evaluation of the state of the kidney is performed later, during the recovery phase following the acute renal damage (11,17). In chronic models the tubular damage prevails over glomerular damage. These models mimic the clinical condition in which patients are in the recovery phase of renal morphophysiology after acute kidney injury caused by aminoglycosides (13) and at the same time, allow us to study what happens in the recovery phase. This could be the most appropriate phase to intervene in survivors of acute kidney injury, since progression towards chronic kidney disease has been observed even several months after the initial injury (18). Gentamicin is the aminoglycoside of choice in most experimental models (19). However, with the use of kanamycin, morphological changes in glomeruli, proximal tubules and interstitium have been described similar to that obtained in studies with gentamicin (11,17). In addition, other glomerular effects of these antibiotics have been described through the use of chronic models of kanamycin nephrotoxicity in rats, in terms of increased mesangial matrix at the expense of increasing the number of mesangial cells and also the presence of glomerular synechiae (17). The presence of synechiae is consistent with the sub-capsular accumulation of filtered proteins, leading to the adhesion of the denuded glomerular basement membrane to the Bowman’s capsule (20). Both glomerular synechiae and mesangial expansion lead to capillary obstruction and this affects the intensity of glomerular filtration (21). The morphological changes in the renal cortex after acute and chronic models of aminoglycoside nephrotoxicity have been described as patchy, due to the simultaneous occurrence of necrosis and regeneration (22,23). Acute models of gentamicin nephrotoxicity have been used to evaluate many protecting candidates (6,24). Chronic models based on treatments with kanamycin have also been used to evaluate possible protective agents addressed to accelerate the recovery of renal morphophysiology after acute renal injury (11,17).

Conclusion

In conclusion, models of nephrotoxicity in rats and mice are essential to achieve a better understanding of the pathophysiology of aminoglycoside-induced damage and to consider strategies for the protection, repair and regeneration, which could be further extrapolated for their use in the clinic (25,26).

Authors’ contribution

All authors wrote the paper equally.

Conflicts of interest

The authors declared no competing interests.

Ethical considerations

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by authors.

Funding/Support

None.
  19 in total

1.  Can glomerulosclerosis be reversed?

Authors:  Agnes B Fogo
Journal:  Nat Clin Pract Nephrol       Date:  2006-06

Review 2.  Aminoglycoside-induced nephrotoxicity--a focus on monitoring: a review of literature.

Authors:  Christopher J Destache
Journal:  J Pharm Pract       Date:  2014-08-14

Review 3.  Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it?

Authors:  Pitchai Balakumar; Ankur Rohilla; Arunachalam Thangathirupathi
Journal:  Pharmacol Res       Date:  2010-04-29       Impact factor: 7.658

Review 4.  Acute kidney injury leading to chronic kidney disease and long-term outcomes of acute kidney injury: the best opportunity to mitigate acute kidney injury?

Authors:  Lakhmir S Chawla
Journal:  Contrib Nephrol       Date:  2011-09-09       Impact factor: 1.580

Review 5.  New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view.

Authors:  Jose M Lopez-Novoa; Yaremi Quiros; Laura Vicente; Ana I Morales; Francisco J Lopez-Hernandez
Journal:  Kidney Int       Date:  2010-09-22       Impact factor: 10.612

6.  Involvement of platelet-activating factor in gentamicin nephrotoxicity in rats.

Authors:  A Rodriguez-Barbero; J M López-Novoa; M Arévalo
Journal:  Exp Nephrol       Date:  1997 Jan-Feb

7.  A comparison between the nephrotoxic profile of gentamicin and gentamicin nanoparticles in mice.

Authors:  Akram Jamshidzadeh; Reza Heidari; Soliman Mohammadi-Samani; Negar Azarpira; Asma Najbi; Parisa Jahani; Narges Abdoli
Journal:  J Biochem Mol Toxicol       Date:  2014-10-08       Impact factor: 3.642

8.  Acute Kidney Injury and Renal Recovery with the Use of Aminoglycosides: A Large Retrospective Study.

Authors:  François Paquette; Amélie Bernier-Jean; Véronique Brunette; Hélène Ammann; Valéry Lavergne; Vincent Pichette; Stéphan Troyanov; Josée Bouchard
Journal:  Nephron       Date:  2015-09-22       Impact factor: 2.847

9.  Halofuginone has a beneficial effect on gentamicin-induced acute nephrotoxicity in rats.

Authors:  Berna Karakoyun; Meral Yuksel; Pinar Turan; Serap Arbak; Inci Alican
Journal:  Drug Chem Toxicol       Date:  2009       Impact factor: 3.356

Review 10.  Animal models of acute renal failure.

Authors:  Amrit Pal Singh; Anselm Junemann; Arunachalam Muthuraman; Amteshwar Singh Jaggi; Nirmal Singh; Kuldeep Grover; Ravi Dhawan
Journal:  Pharmacol Rep       Date:  2012       Impact factor: 3.024

View more
  1 in total

1.  Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.

Authors:  Anthony D Kang; Kenneth P Smith; Anders H Berg; Katherine A Truelson; George M Eliopoulos; Christopher McCoy; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.